Author:
Zola P.,Fuso L.,Mazzola S.,Gadducci A.,Landoni F.,Maggino T.,Sartori E.
Abstract
Nowadays, the cost for oncology diseases is growing rapidly, in particular as a consequence of the introduction of new drugs and new diagnostic procedures, and becoming a considerable percentage of the global healthcare expense. On the other hand, a substantial amount of that cost is considered to be imputable to the follow-up procedures. The aim of our paper is to introduce the debate about follow-up policies adopted in gynecological oncology throughout a literature review just based on cost-effectiveness and cost-efficacy in order to explore if the data are consistent with evidences available in this field. Furthermore, it is discussed if common practice fits the needs of patients, gynecological oncologists, and health service. Despite the fact that in gynecological oncology we must consider different clinical situations concerning each specific neoplasm with their peculiar natural history, some general considerations could be drawn in order to set up future initiatives properly
Subject
Obstetrics and Gynecology,Oncology
Reference45 articles.
1. 2 First annual Nordic Workshop on how to critically appraise and use evidence in decisions about healthcare , National Institute of Public Health, Oslo (Norway), 1996 .
2. 3 T Walley, M Rawlins, and K Stein . NHS Executive Report of the NHS Health Technology Assessment Programme 1996 . London: NHS Executive, 1997 .
3. Efficacy, safety, and cost of new anticancer drugs
4. The wish bias
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献